Drugs / MK-3475A
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07513376 | May 2026 → Aug 2034 expected | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07431827 Background | Mar 2026 → Oct 2039 expected | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-3475A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07431827 ↗ |
| Known as | Pembrolizumab coformulated with berahyaluronidase alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07513376 ↗ |
| Route | Subcutaneous | “administered via SC injection” NCT07431827 ↗ |